Table 1.
Subject characteristics and plasma biochemistry.
| PLA, n = 14 |
EGCG+RES, n = 11 |
||||
|---|---|---|---|---|---|
| Week 0 | Week 12 | Week 0 | Week 12 | P | |
| Age, years | 40±3 | 36±3 | |||
| BMI, kg/m2 | 29.7±1.1 | 30.5±0.7 | |||
| Waist-to-hip-ratio | 0.88±0.03 | 0.88±0.03 | |||
| Diastolic BP, mmHg | 111±3 | 119±2 | |||
| Systolic BP, mmHg | 74±2 | 76±2 | |||
| HbA1c, % | 5.15±0.08 | 5.05±0.06 | |||
| Glucose, mmol/l | 5.11±0.11 | 5.12±0.12 | 5.13±0.13 | 5.08±0.14 | 0.50 |
| 2h-Glucose, mmol/l | 5.29±0.29 | 5.19±0.3 | |||
| Insulin, mU/l | 9.0±1.2 | 10.6±1.1 | 8.7±1.3 | 7.8±1.2 | 0.03 |
| HOMA-IR | 2.03±0.26 | 2.39±0.24 | 1.97±0.29 | 1.77±0.27 | 0.03 |
| Free fatty acids, µmol/l | 532±32 | 491±18 | 497±55 | 532±53 | 0.33 |
| Triacylglycerol, mmol/l | 1.06±0.22 | 1.31±0.24 | 1.75±0.25 | 1.93±0.27 | 0.65 |
| Adiponectin, µg/ml | 8.3±1.0 | 8.6±1.0 | 7.0±1.1 | 7.1±1.1 | 0.77 |
| Leptin, ng/ml | 23.1±4.5 | 24.3±4.5 | 17.8±5.1 | 16.1±5.1 | 0.16 |
| Interleukin-6, pg/ml | 1.00±0.17 | 0.91±0.13 | 0.69±0.19 | 0.77±0.14 | 0.46 |
| Interleukin-8, pg/ml | 9.28±0.94 | 10.32±1.06 | 9.79±1.07 | 9.79±1.20 | 0.43 |
| TNF-α, pg/ml | 2.86±0.24 | 3.3±0.46 | 2.87±0.27 | 2.81±0.52 | 0.26 |
| EGCG, ng/ml | 0±0 | 0±0 | 0±0 | 15±10 | <0.01 |
| RES, ng/ml | 0±0 | 0±0 | 0±0 | 233±55 | <0.01 |
| Dihydro-RES, ng/ml | 0±0 | 0±0 | 0±0 | 177±35 | <0.01 |
BMI, Body-Mass-Index; BP, blood pressure; HbA1c, glycated hemoglobin A 1c; 2h-glucose, plasma glucose after oral glucose-tolerance test; HOMA-IR, Homeostatic Model Assessment of insulin resistance; TNF-α, tumor necrosis factor alpha; EGCG, epigallocatechin-3-gallate; RES, resveratrol. Values given as mean±SEM. P, P-value for statistical significance of time*treatment interaction.